Xtandi 40 MG capsule 120S
Ended Awarded
- Contract number
- SPE2DB26FX1KF
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $273,670
Award facts
- Contract value 100% obligated
- $273,669.84 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $273,669.84 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order was issued on October 23, 2025, with an ultimate completion date of October 24, 2025, and carries no set-aside designation, indicating the award resulted from open competition. DMS Pharmaceutical Group will perform the work at its headquarters location in Park Ridge, Illinois, and will serve as the prime contractor with no identified subcontractor relationships on this award.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. The underlying IDC, designated SPE2DR and awarded in November 2025, carries a $499.999 billion ceiling value and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a regional prime vendor contractor authorized to supply a comprehensive range of branded and generic pharmaceuticals, biologics, and medical consumables to support Department of Defense military healthcare facilities worldwide. The current delivery order for Xtandi, a specialty oncology pharmaceutical, exemplifies the company's role as a critical supplier within the federal pharmaceutical supply chain supporting military medical operations.
Quick answers
Who was awarded contract SPE2DB26FX1KF?
SPE2DB26FX1KF was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 23, 2025.
How much is contract SPE2DB26FX1KF worth?
The government has obligated $273,670 on SPE2DB26FX1KF.
Is contract SPE2DB26FX1KF an order under another contract?
Yes. SPE2DB26FX1KF is a delivery order under SPE2DB22D9353, an indefinite delivery contract.
Was contract SPE2DB26FX1KF competed?
The extent of competition for SPE2DB26FX1KF was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award